While Agios Pharmaceuticals Inc has underperformed by -4.41%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AGIO rose by 71.60%, with highs and lows ranging from $53.28 to $19.80, whereas the simple moving average jumped by 19.79% in the last 200 days.
On September 27, 2024, Leerink Partners Downgraded Agios Pharmaceuticals Inc (NASDAQ: AGIO) to Market Perform. A report published by Cantor Fitzgerald on February 08, 2024, Initiated its previous ‘Overweight’ rating for AGIO. Piper Sandler also rated AGIO shares as ‘Overweight’, setting a target price of $41 on the company’s shares in an initiating report dated February 03, 2023. Goldman November 17, 2022d the rating to Neutral on November 17, 2022, and set its price target from $17 to $32. SVB Leerink July 27, 2022d its ‘Mkt Perform’ rating to ‘Outperform’ for AGIO, as published in its report on July 27, 2022. BofA Securities’s report from December 03, 2021 suggests a price prediction of $54 for AGIO shares, giving the stock a ‘Buy’ rating. Goldman also rated the stock as ‘Sell’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Agios Pharmaceuticals Inc (AGIO)
Further, the quarter-over-quarter increase in sales is 28.35%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Agios Pharmaceuticals Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -44.92% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 9.71, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and AGIO is recording an average volume of 506.12K. On a monthly basis, the volatility of the stock is set at 4.79%, whereas on a weekly basis, it is put at 7.95%, with a loss of -8.84% over the past seven days. Furthermore, long-term investors anticipate a median target price of $54.50, showing growth from the present price of $42.47, which can serve as yet another indication of whether AGIO is worth investing in or should be passed over.
How Do You Analyze Agios Pharmaceuticals Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.05%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 101.60% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AGIO shares are owned by institutional investors to the tune of 101.60% at present.
